TABLE 5.
In vivo activity of ABT-255 against rifampin-resistanta M. tuberculosis ATCC 35838 in CF-1 mice
| Drug and doseb (mg/kg day−1) or group | Mean log10 no. of CFU/lung ± SE | Mean log10 reductionc |
|---|---|---|
| ABT-255 | ||
| 25 | 5.24 ± 0.33 | 2.66 |
| 12.5 | 6.58 ± 0.31 | 1.32 |
| 6.25 | 7.46 ± 0.10 | 0.44 |
| Isoniazid, 25 | 4.48 ± 0.25 | 3.42 |
| Rifampin, 50 | 7.37 ± 0.35 | 0.53 |
| Infected controls | 7.90 ± 0.09 |
a
Inoculum of log10 8.00 mycobacteria.
b
Mice were dosed orally daily, from 7 to 34 days postinfection.
c
Difference in mean log number of CFU from that of the day 35 late control group.